Exelixis expects the agreement to reinforce its in-house pipeline and commercial therapies, including Cabometyx indicated for kidney and liver cancers. Credit: © Exelixis, Inc.

US-based biotechnology company Exelixis has signed an exclusive collaboration, option and license agreement with India-based Aurigene Discovery Technologies for discovery and development of new oncology treatments.

Aurigene will provide Exelixis with access for up to six small molecules programmes, including three existing compounds against predetermined targets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Exelixis expects the agreement to reinforce its in-house pipeline and commercial therapies, which include Cabometyx (cabozantinib), indicated for renal cell carcinoma and hepatocellular carcinoma.

Exelixis scientific strategy executive vice-president and chief scientific officer Peter Lamb said: “Our collaboration has the potential to enhance Exelixis’ early stage pipeline with promising therapeutic candidates while mitigating financial risk for Exelixis through a success-based payment structure.

“Aurigene’s small molecule discovery expertise complements our internal discovery capabilities and gives us access to an expanded range of targets and mechanisms, including covalent inhibition and induced protein degradation.”

Exelixis will pay $10m upfront for in-licensing three existing programmes from Aurigene.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies will also launch three further drug discovery programmes, which will be led by Aurigene. Terms of the agreement include $2.5m in optional payments for each of the new programmes.

Exelixis will additionally provide funding for discovery and preclinical development activities associated with all six programmes.

The company will hold an exclusive option for each programme until the acceptance of the investigational new drug (IND) application.

Should Exelixis exercise the option for a programme, the company will make an option exercise payment and be responsible for that asset’s future clinical development and commercialisation.

Meanwhile, Aurigene will receive potential clinical development, regulatory and sales milestones, along with sales royalties.

Aurigene CEO Murali Ramachandra said: “Exelixis’ demonstrated success in bringing oncology therapies to market, as well as its legacy of drug discovery expertise, make it a natural partner for Aurigene.

“We look forward to combining these complementary skills to drive potential new therapies for the patients that need them.”

As part of the deal, Aurigene retains certain developmental and commercial rights in India and Russia.